Global Antibody Validation Market Overview:
According to the United States FDA, antibody validation is “The process of demonstrating, through the use of specific laboratory investigations, that the performance characteristics of an analytical method are suitable for its intended analytical use.” The performance characteristics may include: proving specificity, proving affinity, and proving reproducibility. Antibodies are used as reagents in life science researches, diagnostics, and clinical tests. Even though their use is widespread use in many areas and a huge investment of time and money for it; there is a lack of guidelines that define how they should be validated before use. Which causes a waste of a lot of time and money. Due to the lack of governing agency for antibody validation; several antibody selling companies are reluctant to validate them. But with a rapidly growing business, validating antibodies is seen as a competitive advantage.
Growth Drivers
- Increasing Demand for Antibody Validation to Check Performance Prior to Their Use
- Growing Use of Antibodies in Treating Immune Deficiencies
Market Trends
- Introduction of Antibody Validation to Reduce Waste of Time and Money
- Increasing Use of Specialised Type of Antibody Validation for Different Applications
Roadblocks
- Concerns About Widespread Implementation of Standardized Process of Antibody Validation
Opportunities
- Surging Demand for Antibody Validation Due to Increasing Use of Antibodies in Biomedical Research
Challenges
- Antibody Performance Can Vary Beyond Validation Efforts Like Shipping and Transportation
- Some Antibody Validation Techniques Require Specialized Equipment
Competitive Landscape:
This market is fragmented among the various regions. The antibody validation market is in the growth phase and has a lot of potential with the increasing use of antibodies. With increasing realization among end-users about the inconsistent quality of antibodies the demand is set to increase for antibody validation. High expertise is required to operate in this market. Also, high R&D cost is required along with capita expenses. There is an opportunity in this market for mergers and acquisitions to increase revenue and R&D capabilities.
Some of the key players profiled in the report are Moderna (United States), Merck (United States), GenScript (United States), Creative Diagnostics (United States), Boster (United States), Abcam (United Kingdom), Cell Signalling Technology (United States), Thermo Fisher Scientific (United States), Bio-Rad Laboratories (United States) and Invitrogen (United States). Additionally, following companies can also be profiled that are part of our coverage like Novus Biologicals (United States), Lifespan Biosciences (United States), OriGene (United States) and Amgen (United States). Considering Market by Antibodies, the sub-segment i.e. IgG will boost the Antibody Validation market. Considering Market by Assays, the sub-segment i.e. Western blot (WB) will boost the Antibody Validation market.
What Can be Explored with the Antibody Validation Market Study
Gain Market Understanding
Identify Growth Opportunities
Analyze and Measure the Global Antibody Validation Market by Identifying Investment across various Industry Verticals
Understand the Trends that will drive Future Changes in Antibody Validation
Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals
Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Antibody Validation market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Antibody Validation market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Venture Capitalists and Private Equity Firms, New Entrants/Investors, Analysts and Strategic Business Planners, Antibody Validation Providers, Raw Material Suppliers, Government Regulatory and Research Organizations, End-Use Industries and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.